CME/CE

Use the tool below to view all available Prova Series

Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
MinuteCE®
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
0.50 program credits
- Lauren A. Byers, MD
0.50 program credits
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC 
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC 
MinuteCE®
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC 
0.50 program credits
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 program credits
MinuteCE®
Transformative Insights: Latest Evidence for B7-H3 ADCs From WCLC and ESMO 2025  
0.50 credits 3 episodes
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 credits 3 episodes
Mastering the Sequence: CELMoDs Across Treatment Lines
Mastering the Sequence: CELMoDs Across Treatment Lines
MinuteCE®
Mastering the Sequence: CELMoDs Across Treatment Lines
1.00 program credit
- Sagar Lonial, MD, FACP
- Noopur Raje, MD
1.00 program credit
Safety First: Navigating CELMoD-Associated Toxicities
Safety First: Navigating CELMoD-Associated Toxicities
MinuteCE®
Safety First: Navigating CELMoD-Associated Toxicities
1.00 program credit
- Joshua Richter, MD
- Noopur Raje, MD
1.00 program credit
Why CELMoDs Matter in Myeloma
Why CELMoDs Matter in Myeloma
MinuteCE®
Why CELMoDs Matter in Myeloma
1.00 program credit
- Sagar Lonial, MD, FACP
1.00 program credit
Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma
Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma
MinuteCE®
Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma
1.00 program credit
- Joshua Richter, MD
- Noopur Raje, MD
1.00 program credit
MinuteCE®
Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma Activity
1.00 credit 10 episodes
- Joshua Richter, MD
- Sagar Lonial, MD, FACP
- Noopur Raje, MD
1.00 credit 10 episodes
Next-Generation Innovations: The Future of CELMoDs in Myeloma
Next-Generation Innovations: The Future of CELMoDs in Myeloma
MinuteCE®
Next-Generation Innovations: The Future of CELMoDs in Myeloma
1.00 program credit
- Noopur Raje, MD
1.00 program credit
Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs
Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs
MinuteCE®
Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs
1.00 program credit
- Joshua Richter, MD
- Sagar Lonial, MD, FACP
1.00 program credit
Data Dive: Clinical Evidence Behind CELMoDs
Data Dive: Clinical Evidence Behind CELMoDs
MinuteCE®
Data Dive: Clinical Evidence Behind CELMoDs
1.00 program credit
- Sagar Lonial, MD, FACP
1.00 program credit
Chairperson Perspective: Acromegaly Care: Individualized Diagnosis and Management Strategies
Chairperson Perspective: Acromegaly Care: Individualized Diagnosis and Management Strategies
CME/CE
Chairperson Perspective: Acromegaly Care: Individualized Diagnosis and Management Strategies
0.25 credits
- Maria Fleseriu, MD, FACE
0.25 credits
Chairperson’s Perspective: Optimizing Perioperative Therapy in Early-Stage NSCLC: A Multidisciplinary Approach
Chairperson’s Perspective: Optimizing Perioperative Therapy in Early-Stage NSCLC: A Multidisciplinary Approach
CME/CE
Chairperson’s Perspective: Optimizing Perioperative Therapy in Early-Stage NSCLC: A Multidisciplinary Approach
0.25 credits
- Heather Wakelee, MD, FASCO
0.25 credits
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
MinuteCE®
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
1.00 program credit
- Paolo A. Ascierto, MD
- Hussein Tawbi, MD, PhD
1.00 program credit
Community Clinic: Translating Data Into Action ─ Practical Strategies for Optimizing First-Line RCC Management
Community Clinic: Translating Data Into Action ─ Practical Strategies for Optimizing First-Line RCC Management
CME/CE
Community Clinic: Translating Data Into Action ─ Practical Strategies for Optimizing First-Line RCC Management
0.25 credits
- Robert J. Motzer, MD
- Elizabeth R. Plimack, MD, MS, FASCO
0.25 credits
HER2 in Bladder Cancer: Breaking Through the Molecular Frontier
HER2 in Bladder Cancer: Breaking Through the Molecular Frontier
CME/CE
HER2 in Bladder Cancer: Breaking Through the Molecular Frontier
0.25 credits
- Vadim S. Koshkin, MD
0.25 credits

CME/CE

Popular

Title

Share on ReachMD